Genus (LON:GNS)‘s stock had its “buy” rating restated by equities research analysts at Peel Hunt in a note issued to investors on Tuesday, Digital Look reports. They presently have a GBX 3,200 ($41.81) price target on the stock. Peel Hunt’s price target indicates a potential upside of 11.03% from the company’s previous close.
A number of other brokerages have also weighed in on GNS. Stifel Nicolaus initiated coverage on shares of Genus in a report on Wednesday, May 29th. They issued a “hold” rating and a GBX 2,685 ($35.08) price objective for the company. Peel Hunt restated a “buy” rating and issued a GBX 3,200 ($41.81) price objective on shares of Genus in a report on Thursday, August 22nd. Finally, Liberum Capital restated a “buy” rating on shares of Genus in a report on Friday, September 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Genus presently has an average rating of “Buy” and a consensus target price of GBX 2,819.17 ($36.84).
Shares of GNS opened at GBX 2,882 ($37.66) on Tuesday. The firm has a market cap of $1.88 billion and a price-to-earnings ratio of 242.18. The company has a debt-to-equity ratio of 21.92, a quick ratio of 1.19 and a current ratio of 2.01. Genus has a fifty-two week low of GBX 2,090 ($27.31) and a fifty-two week high of GBX 2,950 ($38.55). The firm has a 50 day moving average price of GBX 2,615.60 and a 200-day moving average price of GBX 2,501.11.
Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.
Featured Article: What is a Futures Contract?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.